1 / 11

Digoxin use and toxicity

Digoxin use and toxicity. TJ O’Neill 2/5/10. Historical Use of Digoxin. Romans used a non- Digoxin cardiac glycoside derived from sea onion Used sporadically in Middle Ages but popularized in 18 th century Used for dropsy and recognized to decrease edema and slow HR

anana
Download Presentation

Digoxin use and toxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Digoxin use and toxicity TJ O’Neill 2/5/10

  2. Historical Use of Digoxin • Romans used a non-Digoxin cardiac glycoside derived from sea onion • Used sporadically in Middle Ages but popularized in 18th century • Used for dropsy and recognized to decrease edema and slow HR • Withering in 1785 published an account of 156 patients sucessfully treated including Erasmus Darwin 16- 3 William Withering Foxglove 75-60

  3. Digoxin Mechanism of Action • Inhibits Cardiac isoform of Na/K ATPase which indirectly increases intracellular Ca concentration • Increased cardiac output in low output states without increased oxygen consumption • Decreases PCWP • Improves baroreceptor sensitivity in the carotid which may decrease RAAS activation • Increases AV node refractory period by increasing vagal tone

  4. Evidence for Digoxin • In a series of trials beginning in 1988 Digoxin reduced hospitalization but no effect on mortality. • Largest was Digitalis Investigation Group (DIG) 7788 pts radomized to digoxin vs placebo. • No difference in mortality but 25% reduction in hospital admissions • Subgroup analysis showed significant reduction in deaths attributed to “worsening CHF” and almost identical increase in “cardiac death, not due to CHF”

  5. Digoxin Toxicity • Incidence decreasing 2610 reported cases in 2006 compared to 10K for Ca channel blocker and 18K beta blocker toxicity cases • However there were 22 deaths compared to 13 and 4 for CCB and BB during the same year • Increased incidence in elderly as well as decreased renal fxn

  6. Digoxin Toxicity • Cardiac disturbances • GI symptoms • Anorexia, N/V/D, abdominal pain • CNS effects • Weakness, blurred vision, halos around light • In severe cases can cause hyper K • Can be difficult to detect clinically • In Dig trial incidence of “Digoxin toxicity” was 11.9% in Digoxin group and 7.9% in placebo group

  7. Conduction Defects in Digoxin Toxicity • Slows nodal conduction while increasing automaticity • More likely in patients w/ CAD, particularly active ischemia and are potentiated by low Mg, K • Downward slurring of ST • Heart block • VT/VT • -PAT w/ Block • -Bidirectional VT Dali’s Mustache

  8. Pharmacokinetics/dynamics • Half life 36-48 hours in the case of normal renal function (levels stabilize 7 days after dose change • Large reservoir in skeletal muscle • Clearance is primarily renal, but some hepatic metabolism as well • Level should be checked at least 8 hours after dose and may not reflect tissue concentrations if recent dose change. • Level increased by several medications • Verapamil, Diltiazem, amiodarone, itraconazole- decreased clearance • Erythromycin, clarithromycin, tetracycline- decreased gut flora metabolism • Toxicity can be increased by any medication decreasing serum K or potentially affecting renal fxn • Increased level (probably >2.5 but possibly less) + relevant clinical scenario (usually conduction distrubance) = TOXICITY

  9. Treatment • If early after intentional overdose, can give activated charcoal • Bradycardia • If asymptomatic keep serum K at least 4.0 (or higher) • Potassium will affect affinity for Na/K pump • Symptomatic- Atropine, pacing • Digibind (Humanized sheep Mab) • Symptomatic bradycardia not responsive to Atropine • Malignant arrhythmia (particularly in the setting of hyperkalemia) • Hyperkalemia • Important to give adequate dose initially as digoxin levels will be affected for up to 2 weeks • Plasmapheresis will prevent rebound effect • Neither HD nor PD will decrease serum concentation

  10. Prevention • Err on the lower end of dosing, as there is no clear lower end of efficacy. The DIG trial dose of 0.25mg daily is probably not appropriate initial dose for anyone. • Closely monitor drug levels, especially if used with Amio, non DHP CCB, or macrolides • Be particularly cautious following recent hospital discharge

  11. References • Eichhorn EJ et al. Prog Cardiovasc Dis. 44 (4): 251-266, 2002. • Shahbudin H et al. Circulation; 109: 2942-6, 2004 • Hood WB et al. J Cardiac Failure. 10 (2): 155-164, 2004

More Related